Unknown

Dataset Information

0

Delayed short-course treatment with teriparatide (PTH(1-34)) improves femoral allograft healing by enhancing intramembranous bone formation at the graft-host junction.


ABSTRACT: Clinical management of critical bone defects remains a major challenge. Despite preclinical work demonstrating teriparatide (PTH(1-34)) effectiveness in small animals, inconclusive data from clinical trials have raised questions of dose and regimen. To address this, we completed a comprehensive study in the murine femoral allograft model, to assess the effects of dose (0.4, 4, and 40?µg/kg/day) and various treatment regimens on radiographic, histologic, and biomechanical healing at 2, 4, and 9 weeks. Only the high dose (40?µg/kg) of PTH(1-34) demonstrated significant effects when given daily over 9 weeks. Remarkably, equivalent biomechanical results were obtained with delayed, short treatment from 2 to 6 weeks that did not induce a significant increase in endochondral bone formation and callus volume. In contrast, PTH(1-34) treatment from 1 to 5 weeks postop demonstrated similar osteogenic effects as immediate daily treatment for 9 weeks, but failed to achieve a significant increase in biomechanics at 9 weeks. MicroCT and histologic analyses demonstrated that the 2-week delay in treatment allowed for timely completion of the endochondral phase, such that the prominent effects of PTH(1-34) were enhanced intramembranous bone formation and remodeling at the graft-host junction. These findings support the potential use of PTH(1-34) as an adjuvant therapy for massive allograft healing, and suggest that there may be an ideal treatment window in which a short course is administered after the endochondral phase to promote osteoblastic bone formation and remodeling to achieve superior union with modest callus formation.

SUBMITTER: Takahata M 

PROVIDER: S-EPMC3253332 | biostudies-other | 2012 Jan

REPOSITORIES: biostudies-other

altmetric image

Publications

Delayed short-course treatment with teriparatide (PTH(1-34)) improves femoral allograft healing by enhancing intramembranous bone formation at the graft-host junction.

Takahata Masahiko M   Schwarz Edward M EM   Chen Tony T   O'Keefe Regis J RJ   Awad Hani A HA  

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20120101 1


Clinical management of critical bone defects remains a major challenge. Despite preclinical work demonstrating teriparatide (PTH(1-34)) effectiveness in small animals, inconclusive data from clinical trials have raised questions of dose and regimen. To address this, we completed a comprehensive study in the murine femoral allograft model, to assess the effects of dose (0.4, 4, and 40 µg/kg/day) and various treatment regimens on radiographic, histologic, and biomechanical healing at 2, 4, and 9 w  ...[more]

Similar Datasets

| S-EPMC6123430 | biostudies-literature
| S-EPMC2744747 | biostudies-other
| S-EPMC5636088 | biostudies-literature
| S-EPMC8766796 | biostudies-literature
| S-EPMC4940597 | biostudies-literature
| S-EPMC3540116 | biostudies-literature
| S-EPMC7921404 | biostudies-literature
| S-EPMC4886042 | biostudies-literature
| S-EPMC6475622 | biostudies-literature
| S-EPMC5973582 | biostudies-literature